Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 132

Sort by

Sort Order Select

Journal Articles

Administration of Third-Party Virus-Specific T-Cells (VST) at the Time of Initial Therapy for Infection after Haemopoietic Stem Cell Transplant Is Safe and Associated with Favourable Clinical Outcomes (the R3ACT-Quickly trial)

David Gottlieb, MBBS, MD FRACP, FRCPA, Wei Jiang, MBBS, BSc, BA, Selmir Avdic, PhD, Leighton Clancy, BSc PhD, Gaurav Sutrave, MBBS, Caroline M Bateman, PhDMBBS,FRACP,FRCPath,MRCP, Elissa Atkins, RN, Adrian Gabriel Selim, MBBS, Vicki Antonenas, BSc, David Collins, RN BSc (HONS) MN MapptMgt, Janine Street, BSc MSc (Hons), Renee Simms, BSc, Peter J. Shaw, MA,FRACP, David Ritchie, MD PhD, Emily Blyth, B. MDHons), FRACP, FRCPA, PhD

Blood (2019) 134 (Supplement_1): 251.

https://doi.org/10.1182/blood-2019-125166

Published: 2019

Journal Articles

Increased Early Mortality after Fludarabine and Melphalan Conditioning with Peripheral Blood Grafts in Haploidentical SCT with Post-Transplant Cyclophosphamide

Luke Eastburg, MD, David A. Russler-Germain, MDPhDBS, Ramzi Abboud, MD, Peter Westervelt, MD PhD, John F. DiPersio, MD PhD, Michael W. Becker, MD, Neha Kumar, MD, Omar S. Aljitawi, MD, Jeffrey R. Andolina, MD MS, Thomas J Fountaine, MD, Jane L. Liesveld, MD, Eric Huselton, MD

Blood (2019) 134 (Supplement_1): 4496.

https://doi.org/10.1182/blood-2019-129872

Published: 2019

Journal Articles

Comparative Analysis of Immune Reconstitution in HIV-Positive Recipients of Allogeneic and Autologous Stem Cell Transplant on the BMT CTN 0903/AMC-080 and BMT CTN 0803/AMC-071 Trials

Blood (2019) 134 (Supplement_1): 4525.

https://doi.org/10.1182/blood-2019-129488

Published: 2019

Journal Articles

Age Matters: Younger Unrelated PBSC Donors Experience Less G-CSF-Related Symptoms and Have a Faster Emotional Recovery Than Older Donors

Jose ROS Soto, MBBS, Eva Zoubek, PhD, Richard Szydlo, PhD, Paul Johnson, Ann O'Leary, Maria Del Mar Cuadrado, MBBS, Catherine Burlton, J. Alejandro Madrigal, MDPhDDSc,FRCP,FRCPath, Chloe Anthias, MD

Blood (2019) 134 (Supplement_1): 3249.

https://doi.org/10.1182/blood-2019-122304

Published: 2019

Journal Articles

Impact of Donor-Derived CD34+ Infused Cell Dose on Outcomes of Patients Undergoing Allo-HCT Following Reduced Intensity Regimen for Myelofibrosis:a Study from the Chronic Malignancies Working Party of the EBMT

Blood (2019) 134 (Supplement_1): 3338.

https://doi.org/10.1182/blood-2019-123827

Published: 2019

Journal Articles

Human Leukocyte Antigen Matched Unrelated Donors for Patients with Sickle Cell Disease According to Geographic Origin: Results of International Donor Searches

Blood (2019) 134 (Supplement_1): 1021.

https://doi.org/10.1182/blood-2019-124592

Published: 2019

Journal Articles

The Relationship between Transplant Status and Patient-Reported Outcomes in Patients with FLT3 -Mutated Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML): Results from the Phase 3 Admiral Study

David Cella, PhD, Ellen K. Ritchie, MD, Francesco Fabbiano, Arnaud Pigneux, Yoshinobu Kanda, MD PhD, Cristina Ivanescu, PhD, Bhavik J. Pandya, PharmD, Manasee V Shah, MPH

Blood (2019) 134 (Supplement_1): 3850.

https://doi.org/10.1182/blood-2019-123790

Published: 2019

Journal Articles

Outcomes of Therapy Related Acute Lymphoblastic Leukemia in Adults after Allogeneic Stem Cell Transplantation - Twenty-Year Experience from a Tertiary Care Center

RAM V Nampoothiri, Arjun Law, MDDM, Wilson Lam, MD, Zeyad Al-Shaibani, David Loach, MD, Carol Chen, Dennis Dong Hwan Kim, MD PhD, Fotios V. Michelis, MD PhD, Rajat Kumar, MD, Jonas Mattsson, MD, Jeffrey H. Lipton, MD PhD, Auro Viswabandya, MDDM

Blood (2019) 134 (Supplement_1): 5717.

https://doi.org/10.1182/blood-2019-124834

Published: 2019

Journal Articles

Allogeneic CAR-T Cell Therapy for Treatment of Relapse after Allo-HSCT in Patients with Refractory CML Lymphoid Blast Crisis: Significance of HLA Matched Donor/Patient Pair in the Safety/Efficacy of CAR-T Cell Therapy

Kai Sun, MD, Xuejun Zhang, MD, Zhen Wang, MD, Yuqing Chen, MD, Lei Zhang, MD, Wei Cheng, MD, Mingyue Shi, MD, Lei Huo, MD, Yanliang Bai, MD, Xiaona Niu, MD, Honggang Guo, MD, Jing Yang, MD, Chunrong Tong, MD, AlexH Chang, MD, PhD

Blood (2018) 132 (Supplement 1): 4275.

https://doi.org/10.1182/blood-2018-99-115768

Published: 2018

Journal Articles

Daratumumab for Delayed Red Cell Engraftment after Hematopoietic Stem Cell Transplant

Claudia I Chapuy, MD, Richard M Kaufman, MD, Edwin P. Alyea, III, MD, Jean M. Connors, BA,MD

Blood (2018) 132 (Supplement 1): 2545.

https://doi.org/10.1182/blood-2018-99-111880

Published: 2018

Journal Articles

Red Blood Cell Allo-Antibodies after Allogeneic Hematopoietic Stem Cell Transplantation

Astrid Beerlage, MD, Joerg Halter, MD, Sabine Gerull, MD, Michael Medinger, MD, Tanja Ruefli, Georg Stussi, MD, Dominik Heim, MD, Beatrice Drexler, MD, Laura Infanti, MD, Andreas Holbro, MD, Jakob R. Passweg, MDMS, Andreas S. Buser, MD

Blood (2018) 132 (Supplement 1): 2551.

https://doi.org/10.1182/blood-2018-99-116237

Published: 2018

Journal Articles

High Cure Rate By Allogeneic Stem Cell Transplantation for Myelofibrosis Patients Aged 65 or Older

Giulia Daghia, MD PhD, Tatjana Zabelina, MD, Gaby Zeck, Ute-Marie von Pein, MD, Maximilian Christopeit, MD, Christine Wolschke, MD, Francis Ayuketang Ayuk, MD, Nicolaus Kroeger, MD

Blood (2018) 132 (Supplement 1): 4637.

https://doi.org/10.1182/blood-2018-99-113255

Published: 2018

Journal Articles

Successful outcome following allogeneic hematopoietic stem cell transplantation in adults with primary immunodeficiency

Blood (2018) 131 (8): 917–931.

https://doi.org/10.1182/blood-2017-09-807487

Published: 2018

Journal Articles

Transcriptomal Evidence for Dysregulation of Angiogenic Factors and Inflammatory Markers after Allogeneic Hematopoietic Cell Transplantation

Laura F. Newell, MD, Kristina Vartanian, Christina A Harrington, PhD, Shernan G. Holtan, MD

Blood (2017) 130 (Supplement 1): 3259.

https://doi.org/10.1182/blood.V130.Suppl_1.3259.3259

Published: 2017

Journal Articles

Chemotherapy-Refractory Acute Myeloid Leukemia and Outcomes after Allogeneic Stem Cell Transplantation—a Single Center Analysis

Kapil Kohli, MD, Ajoy L. Dias, MD, Neil Dunavin, MD, Leyla Shune, MD, Tara L. Lin, MD, Sunil Abhyankar, MD, Anurag K. Singh, MD, Siddhartha Ganguly, MD, Joseph P. McGuirk, DO, Barry S. Skikne, MD

Blood (2017) 130 (Supplement 1): 5541.

https://doi.org/10.1182/blood.V130.Suppl_1.5541.5541

Published: 2017

Journal Articles

Clonal Evolution in the Setting of Germline Predisposition

Anna L Brown, PhD, Jane Churpek, MD, Christopher N Hahn, PhD, Hamish S Scott, BSc, PhD FFSc (RCPA), FAHMS

Blood (2017) 130 (Supplement 1): SCI-39.

https://doi.org/10.1182/blood.V130.Suppl_1.SCI-39.SCI-39

Published: 2017

Journal Articles

Vaccination with a DNA and MVA ‘Prime-Boost’ Regimen Induces Strong CD8 + T-Cell Responses Against the Immunodominant Minor Histocompatibility Antigen, HA-1: Results of a First-in-Man Phase I Clinical Trial

Charlotte F Inman, BVSc, PhD, Suzy A Eldershaw, BSc. (Hons.), PhD, Hayden Pearce, BSc. (Hons.), PhD, Ben E Abbotts, BSc. (Hons.), MSc., Mirjana Sirovica, BSc(Hons), MSc, Paul Ferguson, MD PhD MRCP, Donna L Walsh, Dip(HE), BSc., Jane Nunnick, BSC. (Hons.), MSc., Shamyla Siddique, BSc.(Hons.), MPhil, Paul Moss, MBBS, PhD FRCP, Ram K Malladi, FRCPath

Blood (2017) 130 (Supplement 1): 1908.

https://doi.org/10.1182/blood.V130.Suppl_1.1908.1908

Published: 2017

Journal Articles

Treatment of Patients with Therapy-Refractory Acute GvHD with the Novel MSC Product "MSC-Ffm" Resulted in Excellent Response and Low Mortality: Post-Approval Observational Data from 69 Consecutive Patients

Blood (2017) 130 (Supplement 1): 514.

https://doi.org/10.1182/blood.V130.Suppl_1.514.514

Published: 2017

Journal Articles

Phase I Trial of Regulatory T-Cell Donor Lymphocyte Infusion Plus Daily Low-Dose Interleukin-2 for Steroid-Refractory Chronic Graft-Versus-Host Disease

Blood (2017) 130 (Supplement 1): 511.

https://doi.org/10.1182/blood.V130.Suppl_1.511.511

Published: 2017

Journal Articles

Syngeneic Fecal Microbiota Transplant Effectively Attenuated Graft-Versus-Host Disease after Bone Marrow Transplantation in Mice

Wei Huang, MD PhD, Amy Bush, BA, Nelson J. Chao, MDM.B.A, Benny J. Chen, MD, Anthony D. Sung, MD

Blood (2017) 130 (Supplement 1): 4435.

https://doi.org/10.1182/blood.V130.Suppl_1.4435.4435

Published: 2017

NARROW

Administration of Third-Party Virus-Specific T-Cells (VST) at the Time of Initial Therapy for Infection after Haemopoietic Stem Cell Transplant Is Safe and Associated with Favourable Clinical Outcomes (the R3ACT-Quickly trial)

Increased Early Mortality after Fludarabine and Melphalan Conditioning with Peripheral Blood Grafts in Haploidentical SCT with Post-Transplant Cyclophosphamide

Comparative Analysis of Immune Reconstitution in HIV-Positive Recipients of Allogeneic and Autologous Stem Cell Transplant on the BMT CTN 0903/AMC-080 and BMT CTN 0803/AMC-071 Trials

Age Matters: Younger Unrelated PBSC Donors Experience Less G-CSF-Related Symptoms and Have a Faster Emotional Recovery Than Older Donors

Impact of Donor-Derived CD34+ Infused Cell Dose on Outcomes of Patients Undergoing Allo-HCT Following Reduced Intensity Regimen for Myelofibrosis:a Study from the Chronic Malignancies Working Party of the EBMT

Human Leukocyte Antigen Matched Unrelated Donors for Patients with Sickle Cell Disease According to Geographic Origin: Results of International Donor Searches

The Relationship between Transplant Status and Patient-Reported Outcomes in Patients with FLT3 -Mutated Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML): Results from the Phase 3 Admiral Study

Outcomes of Therapy Related Acute Lymphoblastic Leukemia in Adults after Allogeneic Stem Cell Transplantation - Twenty-Year Experience from a Tertiary Care Center

Allogeneic CAR-T Cell Therapy for Treatment of Relapse after Allo-HSCT in Patients with Refractory CML Lymphoid Blast Crisis: Significance of HLA Matched Donor/Patient Pair in the Safety/Efficacy of CAR-T Cell Therapy

Daratumumab for Delayed Red Cell Engraftment after Hematopoietic Stem Cell Transplant

Red Blood Cell Allo-Antibodies after Allogeneic Hematopoietic Stem Cell Transplantation

High Cure Rate By Allogeneic Stem Cell Transplantation for Myelofibrosis Patients Aged 65 or Older

Successful outcome following allogeneic hematopoietic stem cell transplantation in adults with primary immunodeficiency

Transcriptomal Evidence for Dysregulation of Angiogenic Factors and Inflammatory Markers after Allogeneic Hematopoietic Cell Transplantation

Chemotherapy-Refractory Acute Myeloid Leukemia and Outcomes after Allogeneic Stem Cell Transplantation—a Single Center Analysis

Clonal Evolution in the Setting of Germline Predisposition

Vaccination with a DNA and MVA ‘Prime-Boost’ Regimen Induces Strong CD8 + T-Cell Responses Against the Immunodominant Minor Histocompatibility Antigen, HA-1: Results of a First-in-Man Phase I Clinical Trial

Treatment of Patients with Therapy-Refractory Acute GvHD with the Novel MSC Product "MSC-Ffm" Resulted in Excellent Response and Low Mortality: Post-Approval Observational Data from 69 Consecutive Patients

Phase I Trial of Regulatory T-Cell Donor Lymphocyte Infusion Plus Daily Low-Dose Interleukin-2 for Steroid-Refractory Chronic Graft-Versus-Host Disease

Syngeneic Fecal Microbiota Transplant Effectively Attenuated Graft-Versus-Host Disease after Bone Marrow Transplantation in Mice

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only